Design Therapeutics

Design Therapeutics DSGN Stock

$9.02   -3.218876%
Add to favorites
Market Cap
$577.61M
LOW - HIGH [24H]
$8.97 - $9.57
VOLUME [24H]
$281.93K
P/E Ratio
0
Earnings per share
-$1.20
ISIN
US25056L1035
Price   Prediction

Design Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Design Therapeutics (DSGN) stock price today is 9.02 USD on Tech Market Large (-3.22% on the day). Updated .

Design Therapeutics DSGN Financial and Trading Overview

Design Therapeutics stock price 9.02 USD
Previous Close 9.47 USD
Open 9.72 USD
Bid 6.81 USD x 200
Ask 9.47 USD x 100
Day's Range 9.22 - 9.72 USD
52 Week Range 7.81 - 17.25 USD
Volume 266.86K USD
Avg. Volume 562.72K USD
Market Cap 596.82M USD
Beta (5Y Monthly) 1.75
PE Ratio (TTM) N/A
EPS (TTM) -1.2 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 21.57 USD

DSGN Valuation Measures

Enterprise Value 390.72M USD
Trailing P/E N/A
Forward P/E -5.9983907
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 2.940063
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -4.807

Trading Information

Design Therapeutics Stock Price History

Beta (5Y Monthly) 1.75
52-Week Change 20.33%
S&P500 52-Week Change 12.00%
52 Week High 17.25 USD
52 Week Low 7.81 USD
50-Day Moving Average 11.36 USD
200-Day Moving Average 12.18 USD

DSGN Share Statistics

Avg. Volume (3 month) 562.72K USD
Avg. Daily Volume (10-Days) 383.25K USD
Shares Outstanding 64.04M
Float 29.98M
Short Ratio 13.03
% Held by Insiders 31.14%
% Held by Institutions 92.45%
Shares Short 6.31M
Short % of Float 12.95%
Short % of Shares Outstanding 9.85%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -23.88%
Return on Equity (ttm) -36.86%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) -61118000 USD
EBITDA -81282000 USD
Net Income Avi to Common (ttm) -74086000 USD
Diluted EPS (ttm) -1.2
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 208.61M USD
Total Cash Per Share (mrq) 3.26 USD
Total Debt (mrq) 2.51M USD
Total Debt/Equity (mrq) 1.24 USD
Current Ratio (mrq) 16.777
Book Value Per Share (mrq) 3.17

Cash Flow Statement

Operating Cash Flow (ttm) -59299000 USD
Levered Free Cash Flow (ttm) -35874248 USD

Profile of Design Therapeutics

Country United States
State CA
City Carlsbad
Address 6005 Hidden Valley Road
ZIP 92011
Phone 858 293 4900
Website https://www.designtx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 60

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

Q&A For Design Therapeutics Stock

What is a current DSGN stock price?

Design Therapeutics DSGN stock price today per share is 9.02 USD.

How to purchase Design Therapeutics stock?

You can buy DSGN shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Design Therapeutics?

The stock symbol or ticker of Design Therapeutics is DSGN.

Which industry does the Design Therapeutics company belong to?

The Design Therapeutics industry is Biotechnology.

How many shares does Design Therapeutics have in circulation?

The max supply of Design Therapeutics shares is 64.04M.

What is Design Therapeutics Price to Earnings Ratio (PE Ratio)?

Design Therapeutics PE Ratio is now.

What was Design Therapeutics earnings per share over the trailing 12 months (TTM)?

Design Therapeutics EPS is -1.2 USD over the trailing 12 months.

Which sector does the Design Therapeutics company belong to?

The Design Therapeutics sector is Healthcare.

Design Therapeutics DSGN included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us US Tech Global Select Market Com NQGS US 11139.01 USD —
-5.31
— — 11086.73 USD — 11742.47 USD — — — —
us US Tech Biotechnology NBI US 6781.89 USD —
-1.73
— — 6767.31 USD — 6980.47 USD — — — —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.02T
Total marketcap
$0
Total volume
BTC 57.46%   •   ETH 9.89%
Dominance
Select currency